by Sermonix Pharmaceuticals | Jul 9, 2020 | News
The multicenter Phase 2 trial, Sermonix’s Evaluation of Lasofoxifene and Abemaciclib in ESR1 Mutations, is projected to begin enrollment in Q3 2020. COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
by Sermonix Pharmaceuticals | Jun 18, 2020 | News
University of Chicago preclinical study compared combination to that of fulvestrant and palbociclib in a mouse intraductal model with cells carrying Y537S ESR1 mutations. Findings will be shared June 22 as part of AACR’s Clinical Endocrinology 2 session. COLUMBUS,...
by Sermonix Pharmaceuticals | Dec 3, 2019 | News
Discussion will examine sexual health and intimacy, bone health, joint and muscle pain, and quality of life issues in metastatic breast cancer COLUMBUS, Ohio, Dec. 03, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company...
by Sermonix Pharmaceuticals | Sep 23, 2019 | News
Biopharmaceutical company is partnering with Sysmex Inostics to identify appropriate study candidates with the OncoBEAM™ ESR1 liquid biopsy test COLUMBUS, Ohio, Sept. 23, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company...
by Sermonix Pharmaceuticals | Sep 23, 2019 | News
Sept. 26 presentation in Chicago demonstrates the need for improvement in practitioners’ understanding of patients’ intimacy concerns COLUMBUS, Ohio, Sept. 25, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on...
by Sermonix Pharmaceuticals | Jun 3, 2019 | News
Sermonix-sponsored University of Chicago preclinical investigation demonstrated: Lasofoxifene alone was significantly more effective than fulvestrant at inhibiting metastasis of both MCF7-Y537S and D538G tumors to the lungs and liver.Lasofoxifene, in combination with...
Recent Comments